Safety evaluation on low-molecular-weight hydroxyethyl starch for volume expansion therapy in pediatric patients: a meta-analysis of randomized controlled trials
Open Access
- 10 March 2015
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-10
Abstract
Hydroxyethyl starch (HES) has been widely used for volume expansion, but its safety in adult patients has been questioned recently. The aim of this meta-analysis is to see whether or not HES has any adverse effect in pediatric patients. Randomized controlled trials (RCTs) involving pediatric patients who received 6% low-molecular-weight HES, published before January 2014, were searched for in Pubmed, Embase database and Cochrane Library. Two reviewers independently extracted the valid data, including the mortality, renal function, coagulation, blood loss, hemodynamic changes, and length of hospital and ICU stay. All data were analyzed by I 2-test, and the results of statistical analysis were displayed in forest plots. Possible publication bias was tested by funnel plots. Bayesian analysis was performed using WinBUGS with fixed and random effects models. A total of 13 RCTs involving 1,156 pediatric patients were finally included in this meta-analysis. Compared with other fluids, HES did not significantly decrease the mortality (RR = -0.01; 95%CI: 0.05 to 0.03; P = 0.54; I 2 = 6%), creatinine level (I 2-test: MD = 1.81; 95%CI: -0.35 to 3.98; P = 0.10;I 2 = 0%; Bayesian analysis: Fixed effect model MD = 1.77; 95%CI: -0.07 to 3.6; Random effects model MD = 1.78; 95%CI: -1.86 to 5.33), activated partial thromboplastin time (MD = 0.01; 95%CI: -1.05 to 1.07; P = 0.99; I 2 = 42%), and blood loss (MD = 17.72; 95%CI: -41.27 to 5.82; P = 0.10; I 2 = 0%) in pediatric patients. However, HES significantly decreased the blood platelet count (MD = 20.99; 95%CI: -32.08 to -9.90; P = 0.0002; I 2 = 28%) and increased the length of ICU stay (MD = 0.94; 95%CI: 0.18 to 1.70; P = 0.02; I 2 = 46%). Volume expansion with 6% HES significantly decreased the platelet count and increased the length of ICU stay, also might have an adverse effect on renal function. Therefore HES is not recommended for pediatric patients, which safety needs more high quality RCTs and studies to confirm in future.Keywords
This publication has 43 references indexed in Scilit:
- Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive CareNew England Journal of Medicine, 2012
- Evidence Synthesis for Decision Making 2Medical Decision Making, 2012
- Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe SepsisNew England Journal of Medicine, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Phase II trial on the use of Dextran 70 or starch for supportive therapy in Kenyan children with severe malaria*Critical Care Medicine, 2010
- Perioperative volume replacement in children undergoing cardiac surgery: Albumin versus hydroxyethyl starch 130/0.4*Critical Care Medicine, 2009
- HES 130/0.4 (Voluven®) or human albumin in children younger than 2 yr undergoing non-cardiac surgery. A prospective, randomized, open label, multicentre trialEuropean Journal of Anaesthesiology, 2008
- Comparison of Three Fluid Solutions for Resuscitation in Dengue Shock SyndromeNew England Journal of Medicine, 2005
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996